How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries? January 24, 2023 Issue Brief The brief provides a quick explainer of the prescription drug provisions in the Inflation Reduction Act signed into law on August 16, 2022 and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
How Would the Prescription Drug Provisions in the Senate Reconciliation Proposal Affect Medicare Beneficiaries? July 27, 2022 Issue Brief The brief provides a quick explainer of the prescription drug provisions in legislative text released by the Senate Finance Committee to be included in a forthcoming reconciliation bill and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries June 10, 2021 Issue Brief The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S. This brief analyzes the cost implications for Medicare and beneficiaries associated with Biogen’s new FDA-approved Alzheimer’s drug, which will cost $56,000 per year.
How Many Teachers Are at Risk of Serious Illness If Infected with Coronavirus? July 10, 2020 Issue Brief As the nation continues to struggle to contain the spread of coronavirus, there is considerable debate about when and how to reopen schools. This analysis finds that one in four teachers (24%, or about 1.47 million people), have a condition that puts them at higher risk of serious illness from coronavirus.
About 1.5 Million Teachers are at Higher Risk of Serious Illness From COVID-19 July 10, 2020 News Release As local, state and federal official debate when and how to reopen schools across the nation, a new KFF analysis estimates nearly 1.5 million teachers have health conditions that put them at higher risk of serious illness if they were to contract COVID-19. This represents nearly one in four (24%)…
New Analysis Compares Prescription Drug Spending and Use Across Large Employer Plans, Medicare, and Medicaid May 20, 2019 News Release As policymakers debate how to address the high cost of prescription drugs, a new KFF analysis compares data on prescription drug spending and use across large employer plans, Medicare Part D and Medicaid, and provides context for policy discussions about different approaches to curb rising drug costs that would affect…
How Does Prescription Drug Spending and Use Compare Across Large Employer Plans, Medicare Part D, and Medicaid? May 20, 2019 Issue Brief Prescription drug costs are a pressing concern for both consumers and policymakers. This analysis compares prescription drug spending and use in large private employer plans, Medicare Part D, and Medicaid, based primarily on claims data by payer, which does not account for rebates.
The Silent Affordability Crisis Facing Sick People May 8, 2019 Perspective In this Axios column, Drew Altman shows that employer coverage for lower wage workers is much worse than ACA marketplace coverage for similar populations. It’s a bigger problem we need to talk about more, he says.